UK to offer first weight loss med for diabetes prevention

30 October 2020

A positive reimbursement decision in the UK means that Novo Nordisk’s (NOV: N) Saxenda (liraglutide) will be available through the country’s national healthcare provider as a weight management treatment.

Saxenda is recommended alongside a reduced calorie diet and increased physical activity, for certain obese adults with pre-diabetes and a high risk of cardiovascular disease.

It is the first weight loss pharmacotherapy to be recommended by the National Institute for Health and Care Excellence (NICE), for the prevention of type 2 diabetes in certain groups of patients.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK